FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3162183759> ?p ?o ?g. }

• W3162183759 abstract "Exebacase, a recombinantly produced lysin has recently (i) reported proof-of-concept data from a phase II study in S. aureus bacteremia and (ii) demonstrated antibiofilm activity in vitro against S. epidermidis . In patients with relapsing multidrug-resistant (MDR) S. epidermidis prosthetic knee infection (PKI), the only surgical option is prosthesis exchange. In elderly patients who have undergone several revisions, prosthesis explantation could be associated with definitive loss of function and mortality. In our BJI reference regional center, arthroscopic debridement and implant retention with local administration of exebacase (LysinDAIR) followed by suppressive tedizolid as salvage therapy is proposed for elderly patients with recurrent MDR S. epidermidis PKI with no therapeutic option or therapeutic dead end (for whom revision or transfemoral amputation is not feasible and no other oral option is available). Each use was decided in agreement with the French health authority and in accordance with the local ethics committee. A written consent was obtained for each patient. Exebacase (75 mg/mL; 30 mL) was administered directly into the joint during arthroscopy. Four patients (79–89 years old) were treated with the LysinDAIR procedure. All had several previous prosthetic knee revisions without prosthesis loosening. Three had relapsing PKI despite suppressive antibiotics following open DAIR. Two had clinical signs of septic arthritis; the two others had sinus tract. After the LysinDAIR procedure, no adverse events occurred during arthroscopy; all patients received daptomycin 8 mg/kg and linezolid 600 mg bid (4–6 weeks) as primary therapy, followed by tedizolid 200 mg/day as suppressive therapy. At 6 months, recurrence of the sinus tract occurred in the two patients with sinus tract at baseline. After &gt;1 year follow up, the clinical outcome was favorable in the last two patients with total disappearance of clinical signs of septic arthritis even if microbiological persistence was detected in one of them. Exebacase has the potential to be used in patients with staphylococci PKI during arthroscopic DAIR as salvage therapy to improve the efficacy of suppressive antibiotics and to prevent major loss of function." @default.
• W3162183759 created "2021-05-24" @default.
• W3162183759 creator A5008782369 @default.
• W3162183759 creator A5010821905 @default.
• W3162183759 creator A5018967088 @default.
• W3162183759 creator A5020778242 @default.
• W3162183759 creator A5024694820 @default.
• W3162183759 creator A5032910149 @default.
• W3162183759 creator A5037619534 @default.
• W3162183759 creator A5055756681 @default.
• W3162183759 creator A5057355995 @default.
• W3162183759 creator A5063696310 @default.
• W3162183759 creator A5067674374 @default.
• W3162183759 creator A5071595675 @default.
• W3162183759 creator A5091842926 @default.
• W3162183759 date "2021-05-14" @default.
• W3162183759 modified "2023-09-26" @default.
• W3162183759 title "Arthroscopic “Debridement and Implant Retention” With Local Administration of Exebacase (Lysin CF-301) Followed by Suppressive Tedizolid as Salvage Therapy in Elderly Patients for Relapsing Multidrug-Resistant S. epidermidis Prosthetic Knee Infection" @default.
• W3162183759 cites W2035839449 @default.
• W3162183759 cites W2048860161 @default.
• W3162183759 cites W2079575346 @default.
• W3162183759 cites W2093037924 @default.
• W3162183759 cites W2171117330 @default.
• W3162183759 cites W2336577555 @default.
• W3162183759 cites W2416820840 @default.
• W3162183759 cites W2556179740 @default.
• W3162183759 cites W2562856977 @default.
• W3162183759 cites W2611698472 @default.
• W3162183759 cites W2766601565 @default.
• W3162183759 cites W2767892905 @default.
• W3162183759 cites W2789576421 @default.
• W3162183759 cites W2803817679 @default.
• W3162183759 cites W2883285900 @default.
• W3162183759 cites W2894182618 @default.
• W3162183759 cites W2898384637 @default.
• W3162183759 cites W2899632438 @default.
• W3162183759 cites W2903592374 @default.
• W3162183759 cites W2912207523 @default.
• W3162183759 cites W2913591780 @default.
• W3162183759 cites W2933066688 @default.
• W3162183759 cites W2956924929 @default.
• W3162183759 cites W2966308689 @default.
• W3162183759 cites W2973532544 @default.
• W3162183759 cites W2978889934 @default.
• W3162183759 cites W2984537158 @default.
• W3162183759 cites W4247523090 @default.
• W3162183759 cites W57483582 @default.
• W3162183759 doi "https://doi.org/10.3389/fmed.2021.550853" @default.
• W3162183759 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8163228" @default.
• W3162183759 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34055817" @default.
• W3162183759 hasPublicationYear "2021" @default.
• W3162183759 type Work @default.
• W3162183759 sameAs 3162183759 @default.
• W3162183759 citedByCount "6" @default.
• W3162183759 countsByYear W31621837592021 @default.
• W3162183759 countsByYear W31621837592022 @default.
• W3162183759 countsByYear W31621837592023 @default.
• W3162183759 crossrefType "journal-article" @default.
• W3162183759 hasAuthorship W3162183759A5008782369 @default.
• W3162183759 hasAuthorship W3162183759A5010821905 @default.
• W3162183759 hasAuthorship W3162183759A5018967088 @default.
• W3162183759 hasAuthorship W3162183759A5020778242 @default.
• W3162183759 hasAuthorship W3162183759A5024694820 @default.
• W3162183759 hasAuthorship W3162183759A5032910149 @default.
• W3162183759 hasAuthorship W3162183759A5037619534 @default.
• W3162183759 hasAuthorship W3162183759A5055756681 @default.
• W3162183759 hasAuthorship W3162183759A5057355995 @default.
• W3162183759 hasAuthorship W3162183759A5063696310 @default.
• W3162183759 hasAuthorship W3162183759A5067674374 @default.
• W3162183759 hasAuthorship W3162183759A5071595675 @default.
• W3162183759 hasAuthorship W3162183759A5091842926 @default.
• W3162183759 hasBestOaLocation W31621837591 @default.
• W3162183759 hasConcept C126322002 @default.
• W3162183759 hasConcept C141071460 @default.
• W3162183759 hasConcept C197934379 @default.
• W3162183759 hasConcept C2777438270 @default.
• W3162183759 hasConcept C2777949923 @default.
• W3162183759 hasConcept C2778715743 @default.
• W3162183759 hasConcept C2778980435 @default.
• W3162183759 hasConcept C2779489039 @default.
• W3162183759 hasConcept C2781411149 @default.
• W3162183759 hasConcept C2781414143 @default.
• W3162183759 hasConcept C523546767 @default.
• W3162183759 hasConcept C54355233 @default.
• W3162183759 hasConcept C71924100 @default.
• W3162183759 hasConcept C86803240 @default.
• W3162183759 hasConceptScore W3162183759C126322002 @default.
• W3162183759 hasConceptScore W3162183759C141071460 @default.
• W3162183759 hasConceptScore W3162183759C197934379 @default.
• W3162183759 hasConceptScore W3162183759C2777438270 @default.
• W3162183759 hasConceptScore W3162183759C2777949923 @default.
• W3162183759 hasConceptScore W3162183759C2778715743 @default.
• W3162183759 hasConceptScore W3162183759C2778980435 @default.
• W3162183759 hasConceptScore W3162183759C2779489039 @default.
• W3162183759 hasConceptScore W3162183759C2781411149 @default.
• W3162183759 hasConceptScore W3162183759C2781414143 @default.
• W3162183759 hasConceptScore W3162183759C523546767 @default.
• W3162183759 hasConceptScore W3162183759C54355233 @default.
• W3162183759 hasConceptScore W3162183759C71924100 @default.
• W3162183759 hasConceptScore W3162183759C86803240 @default.

• next